Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings Inc    ZBH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biomet 3Q Loss Widens On Charges; Sales Grow 5%

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/11/2012 | 04:51pm CEST

("Biomet 3Q Loss Widens On Charges; Sales Grow 5%," at 7:03 a.m. EDT, misstated the hip sales increase in the sixth paragraph. The correct version follows:)

Biomet Inc.'s fiscal third-quarter loss widened on merger-related costs as strong sales for sports medicine, extremities and trauma helped drive the orthopedic medical-device maker's top-line growth.

Though privately held, Biomet's results are closely watched because the company reports earlier than larger competitors--such as Zimmer Holdings Inc. (>> Zimmer Holdings, Inc.), Stryker Corp. (SYK) and Johnson & Johnson (>> Johnson & Johnson)--and could foreshadow industry trends.

Biomet has seen its losses widen in recent quarters, weighed down by charges related to its $11.4 billion buyout in 2007 by a private-equity consortium including affiliates from The Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts & Co. and TPG. Sales have also been weak as patients, worried about out-of-pocket costs or long absences from work to recover, opt to defer hip and knee-replacement procedures. Biomet has said it is unclear when demand will come back.

For the quarter ended Feb. 29, Biomet reported a loss of $16.5 million, compared with a loss of $11.6 million a year earlier. Excluding merger and other special items, adjusted earnings fell to $55.1 million from $63.8 million. Sales jumped 4.5% to $708.9 million.

Gross margin slipped to 69% from 69.3%.

The company, which distributes products in about 90 countries, said worldwide hip sales increased 6%, while worldwide knee sales grew 4%. Sales for sports medicine, extremities and trauma were up 16%, while the spine and bone healing segment saw a 5% drop.

U.S. sales grew 5% while Europe sales rose 2.1%. International sales, which include Canada, South America, Mexico and the Asia-Pacific region, jumped 7.2%.

Last week, Biomet made a binding offer to acquire the global trauma business of Johnson & Johnson's DePuy Orthopaedics Inc. for about $280 million in cash, a deal the company said would greatly expand its sports, extremities and trauma business. Biomet also recently agreed to pay $23 million in penalties to settle U.S. allegations that it bribed doctors in Brazil, China and other countries over a period of years.

--By Anne Pallivathuckal and Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

Stocks mentioned in the article : Zimmer Holdings, Inc., Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIMMER BIOMET HOLDINGS INC
06/23 Global Medical Implants Market 2017 - Zimmer Biomet, Medtronic, St.Jude Medic..
06/21 ZIMMER BIOMET HOLDINGS INC : ex-dividend day
06/15 ZIMMER BIOMET HOLDINGS INC : Featured Company News - Zimmer Biomet's China Manuf..
06/13 ZIMMER BIOMET HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (..
06/13 ZIMMER BIOMET : Announces Resolution of FDA Warning Letter Related to Its Zhejia..
06/09 ZIMMER BIOMET : Announces Quarterly Dividend for Second Quarter of 2017
06/05 ZIMMER BIOMET : Named Top Workplace on Forbes' "America's Best Large Employers o..
06/05 ZIMMER BIOMET : to Present at the Bank of America Merrill Lynch 2017 Health Care..
06/05 ZIMMER BIOMET : Announces Quarterly Dividend for Second Quarter of 2017
05/30 ZIMMER BIOMET : May 30, 2017 Zimmer Biomet Announces Quarterly Dividend for Seco..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/16 Earnings drag on European shares, though Vodafone lifts telcos
05/09 French outbound M&A driven to decade high by big deals
05/06DJProfits Jump, Spending Lags -- WSJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
06/21 Smith & Nephew Innovates In Wound Care, But No Trade Sale In Sight
06/13 Zimmer Biomet resolves FDA Warning Letter related to China manufacturing site
05/30 Zimmer Biomet declares $0.24 dividend
05/30 FDA recalls 33 Zimmer Biomet implantable spinal fusion stimulators
05/25 Tracking Larry Robbins's Glenview Capital Management Portfolio - Q1 2017 Upda..
Advertisement
Financials ($)
Sales 2017 7 866 M
EBIT 2017 2 490 M
Net income 2017 1 207 M
Debt 2017 9 294 M
Yield 2017 0,73%
P/E ratio 2017 24,32
P/E ratio 2018 18,93
EV / Sales 2017 4,49x
EV / Sales 2018 4,21x
Capitalization 26 030 M
More Financials
Chart ZIMMER BIOMET HOLDINGS INC
Duration : Period :
Zimmer Biomet Holdings Inc Technical Analysis Chart | ZBH | US98956P1021 | 4-Traders
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOL...
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 132 $
Spread / Average Target 2,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David C. Dvorak President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Adrian Furey Senior VP-Global Operations & Logistics
Daniel P. Florin Chief Financial Officer & Senior Vice President
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS..25.09%26 030
MEDTRONIC PLC25.23%122 105
BAXTER INTERNATIONAL38.43%33 370
C R BARD INC40.65%22 882
HOYA CORPORATION15.48%19 898
TERUMO CORP4.97%15 488
More Results